About the Authors
- Christiane Desel
-
* E-mail: christiane.desel@uk-erlangen.de (CD); roland.lang@uk-erlangen.de (RL)
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Kerstin Werninghaus
-
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Manuel Ritter
-
Affiliation Institute of Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- Katrin Jozefowski
-
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Jens Wenzel
-
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Norman Russkamp
-
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Ulrike Schleicher
-
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
- Dennis Christensen
-
Affiliation Statens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark
- Stefan Wirtz
-
Affiliation Medical Clinic 1, Gastroenterology, Pneumology and Endocrinology, University Hospital Erlangen, Erlangen, Germany
- Carsten Kirschning
-
Affiliation Institut für Medizinische Mikrobiologie, Essen, Germany
- Else Marie Agger
-
Affiliation Statens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark
- Clarissa Prazeres da Costa
-
Affiliation Institute of Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
- Roland Lang
-
* E-mail: christiane.desel@uk-erlangen.de (CD); roland.lang@uk-erlangen.de (RL)
Affiliation Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, Erlangen, Germany
Competing Interests
CAF01 is currently in clinical development at Statens Serum Institut and three clinical phase 1 studies have been conducted successfully. With regards to the intellectual property status on CAF01, the Statens Serum Institut has one issued patent (WO2006002642). None of the coauthors are registered as inventors on the patent and the full right has been transferred to Statens Serum Institut. EMA and/or DC are furthermore coinventors on patents on related technologies (WO2005004911A2, WO2009003474, WO2010054654, PCT/DK2012/000080) for all of which the full right has been transferred to Statens Serum Institut. This does not alter the authors’ adherence to the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CD KW RL. Performed the experiments: CD KW MR KJ NR JW. Analyzed the data: CD KW RL JW. Contributed reagents/materials/analysis tools: US DC SW CK EMA CPdC. Wrote the paper: CD MR CPdC RL.